Previous close | 0.5400 |
Open | 0.5350 |
Bid | 0.5050 x 3162600 |
Ask | 0.5400 x 365000 |
Day's range | 0.5050 - 0.5350 |
52-week range | 0.2950 - 0.6450 |
Volume | 287,373 |
Avg. volume | 443,551 |
Market cap | 95.537M |
Beta (5Y monthly) | 0.36 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0460 |
Earnings date | 27 Aug 2018 - 31 Aug 2018 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Australian-based regenerative medicine company, Orthocell Ltd (ASX:OCC, "Orthocell" or the "Company"), has achieved US 510k clearance to market and supply its collagen medical device Striate+TM in the US dental bone and tissue regeneration market.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The CEO of Orthocell Limited (ASX:OCC) is Paul Anderson, and this article examines the executive's compensation...